Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:

NCT ID: NCT03275285 Active, not recruiting - Plasma Cell Myeloma Clinical Trials

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

IKEMA
Start date: October 25, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.

NCT ID: NCT03275103 Recruiting - Multiple Myeloma Clinical Trials

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Start date: September 19, 2017
Phase: Phase 1
Study type: Interventional

This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).

NCT ID: NCT03274219 Completed - Multiple Myeloma Clinical Trials

Study of bb21217 in Multiple Myeloma

Start date: August 16, 2017
Phase: Phase 1
Study type: Interventional

Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).

NCT ID: NCT03271632 Recruiting - Multiple Myeloma Clinical Trials

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Start date: July 15, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

NCT ID: NCT03269136 Completed - Multiple Myeloma Clinical Trials

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Start date: November 29, 2017
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

NCT ID: NCT03267888 Completed - Clinical trials for Recurrent Plasma Cell Myeloma

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Start date: May 29, 2018
Phase: Phase 1
Study type: Interventional

This pilot clinical trial studies the side effects of pembrolizumab and radiation therapy in treating patients with stage I-III multiple myeloma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may block cancer growth in different ways by targeting certain cells. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving pembrolizumab and radiation therapy may work better in treating patients with stage I-III multiple myeloma.

NCT ID: NCT03266692 Terminated - Multiple Myeloma Clinical Trials

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.

NCT ID: NCT03262389 Completed - Multiple Myeloma Clinical Trials

Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

Start date: September 19, 2017
Phase: Phase 2
Study type: Interventional

Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.

NCT ID: NCT03256045 Terminated - Clinical trials for Recurrent Plasma Cell Myeloma

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Start date: February 8, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well panobinostat, carfilzomib, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using multiple myeloma cells from patients' blood samples, the researchers will do laboratory tests to look at how well each of the drugs, alone and in different combinations, kill multiple myeloma cells. If the laboratory tests work well, they may be used in the future to help plan treatment for future patients.

NCT ID: NCT03246529 Active, not recruiting - Multiple Myeloma Clinical Trials

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous TransplantatIon in Subjects With MM

GENESIS
Start date: March 23, 2018
Phase: Phase 3
Study type: Interventional

A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.